Arvinas, Inc. announced that John Houston, Ph.D., Chairperson, Chief Executive Officer (CEO), and President, has informed the Board of Directors of his plans to retire from his role as President and CEO. His retirement will occur following the search for and appointment of the company's new CEO.
Dr. Houston will remain Chairperson of Arvinas’ Board of Directors upon his retirement as President and CEO. The Board of Directors has initiated a search for his replacement, aiming to ensure a smooth leadership transition.
During his eight-year tenure as CEO, Dr. Houston was instrumental in advancing six programs into the clinic, reporting the first positive pivotal Phase 3 trial for a PROTAC, and demonstrating the first orally administered PROTAC to achieve pharmacodynamic activity in the central nervous system.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.